Endomorphin-1: induction of motor behavior and lack of receptor desensitization

A Mehta1, G Bot, T Reisine

  • 1Department of Neurology, University of California, Los Angeles School of Medicine, Los Angeles, California 90095, USA.

Insights

Endomorphin-1, a mu-opioid receptor agonist, induces sustained orofacial dyskinesia when administered to the rat globus pallidus, suggesting a role in hyperkinetic movement disorders.

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Endomorphins are novel endogenous agonists for mu-opioid receptors.
  • Their functions beyond analgesia, particularly in motor control, remain largely unknown.
  • The globus pallidus is rich in mu-opioid receptors and implicated in motor regulation.

Purpose of the Study:

  • To investigate the behavioral effects of endomorphin-1 in the globus pallidus.
  • To determine the role of pallidal mu-opioid receptors in motor control.
  • To explore the potential involvement of endomorphins in hyperkinetic movement disorders.

Main Methods:

  • Bilateral administration of endomorphin-1 into the globus pallidus of rats.
  • Dose-response and time-course analysis of induced behaviors.
  • Assessment of mu-opioid receptor desensitization in vitro.
  • Pharmacological blockade using naloxone and CTOP.
  • Infusion of a selective mu-opioid agonist (DAMGO).

Main Results:

  • Endomorphin-1 induced dose-dependent orofacial dyskinesia in rats.
  • The motor effect was sustained for 60 minutes, indicating no rapid desensitization.
  • Endomorphin-1 did not desensitize mu-opioid receptors' ability to inhibit adenylate cyclase.
  • The effects were blocked by naloxone and CTOP, confirming mu-opioid receptor involvement.
  • DAMGO also induced transient orofacial dyskinesia.

Conclusions:

  • Endogenous mu-opioid agonists, like endomorphin-1, can induce motor disturbances.
  • Sustained activation of pallidal opioid receptors may contribute to hyperkinetic movement disorders.
  • Endomorphins represent a potential target for understanding and treating movement abnormalities.